Genocea Awarded World Vaccine Congress 2017 Industry

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
26
Genocea Awarded World Vaccine Congress 2017 Industry Excellence Award for Best Therapeutic Vaccine for GEN-003 for Genital Herpes

CAMBRIDGE, Mass., April 11, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA ), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it has been awarded the World Vaccine Congress 2017 Industry Excellence award for best therapeutic vaccine for GEN-003, an immunotherapy to treat genital herpes, which is expected to be Phase 3 ready by the end of 2017.

In addition, the company is giving two oral presentations and participating on a panel at the congress, which is taking place from April 10-12 in Washington DC. The two presentations highlight the success to date of Genocea’s ATLAS™ technology, a proprietary T cell immune response screening platform designed to identify clinically relevant T cell antigens. Using ATLAS, Genocea is building a pipeline of candidates that includes GEN-003 and GEN-009, a neoantigen cancer vaccine, for which the company expects to file an Investigational New Drug (IND) application by the end of 2017.

  • “Developing an HSV vaccine to control clinical recurrences and viral shedding” Tuesday, April 11 at 12:10 pm ET Thomas Heineman, M.D., Ph.D., Genocea’s Vice President of Clinical Development In his presentation, Dr. Heineman will provide a comprehensive overview of GEN-003: its rational design and positive clinical results to date.
  • “Comprehensive profiling of T cell responses to putative neoantigens reveals smarter targets for cancer immunotherapy” Wednesday, April 12 at 12:00 pm ET Jessica Baker Flechtner, Ph.D., Genocea’s Chief Scientific Officer In her presentation, Dr. Flechtner will provide an overview of the company’s ATLAS technology: its advantages over predictive methods of antigen identification, and how Genocea is using ATLAS to develop neoantigen cancer vaccines and to help identify patients most likely to benefit from checkpoint blockade therapies.

In addition, Dr. Flechtner will be participating on the following panel:

  • “For vaccines that are being paired with adjuvant or checkpoint blockade therapies, are we working with the right antigenic targets?” Tuesday, April 11 at 5:40 pm ET

About GEN-003 GEN-003 is an investigational T cell-directed immunotherapy designed to elicit both a T cell and B cell (antibody) immune response in patients with genital herpes. In multiple Phase 2 randomized, placebo-controlled clinical trials, GEN-003 has demonstrated the ability to statistically significantly reduce the clinical signs of genital herpes and the rate of viral shedding. The immunotherapy was designed using Genocea's ATLAS™ platform, which profiled the comprehensive spectrum of actual T cell responses mounted by humans in response to HSV-2 to identify antigen targets that drive protective T cell responses to the virus. If successfully developed and marketed, GEN-003 would be the first new therapy in more than 20 years to treat the large and unsatisfied global genital herpes patient population.

About ATLAS™ and GEN-009 ATLAS is a first-of-its-kind proprietary antigen identification screening platform designed to find antigens associated with protective T cell responses. ATLAS provides a panoramic and comprehensive perspective of actual human T cell responses to every potential antigen from a pathogen or tumor. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS to identify clinically relevant antigens of T cells, potentially increasing the likelihood of successful clinical development of vaccines and immunotherapies. Genocea used ATLAS to identify the target antigens in its lead clinical candidate, GEN-003, an investigational immunotherapy to treat genital herpes, and is currently using ATLAS to develop its lead immuno-oncology candidate GEN-009, a neoantigen cancer vaccine. Genocea is also using ATLAS to comprehensively profile responders and non-responders to checkpoint blockade therapies with the goal of improving patient selection and outcomes for clinical practice.

About Genocea Biosciences, Inc. Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea used ATLAS to identify the antigens in its lead clinical candidate, GEN-003, an investigational immunotherapy to treat genital herpes, and is currently using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines and to identify T cell response signatures of cancer patients treated with checkpoint blockade therapies to potentially improve clinical practice. Genocea expects GEN-003 to be ready to begin Phase 3 development and to file an IND for its neoantigen cancer vaccine candidate GEN-009 by the end of 2017. For more information, please visit the company's website at www.genocea.com .

Forward-Looking Statements Statements herein relating to future business performance, conditions or strategies and other financial and business matters, including expectations regarding clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including Genocea's ability to progress any product candidates in preclinical or clinical trials; the ability of ATLAS to identify promising oncology vaccine and immunotherapy product candidates; the scope, rate and progress of its preclinical studies and clinical trials and other research and development activities; anticipated clinical trial results; current results may not be predictive of future results; even if the data from preclinical studies or clinical trials is positive, regulatory authorities may require additional studies for approval and the product may not prove to be safe and efficacious; Genocea's ability to enter into future collaborations with industry partners and the government and the terms, timing and success of any such collaboration; risks associated with the manufacture and supply of clinical and commercial product; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; Genocea's ability to obtain rights to technology; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; the rate of cash utilized by Genocea in its business and the period for which existing cash will be able to fund such operation; Genocea's ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity or debt financing or otherwise; general business conditions; competition; business abilities and judgment of personnel; the availability of qualified personnel and other factors set forth under "Risk Factors" in Genocea's Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and other filings with the Securities and Exchange Commission (the "SEC"). Further information on the factors and risks that could affect Genocea's business, financial conditions and results of operations is contained in Genocea's filings with the SEC, which are available at www.sec.gov . These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements.

For media: Jennifer LaVin 207-360-0473 jennifer.lavin@genocea.com For investors: Jonathan Poole 617-876-8191 jonathan.poole@genocea.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 495

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 0

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 269

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 287

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 399

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 416

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 349

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 176

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 0

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading

Top 5 Most Recently Viewed Articles

European Frozen Food Market Set for Major Growth, Companies Thrive

Updated Category News Views 277

European Frozen Food Market Set for Major Growth The frozen food market across Europe is poised for remarkable growth in the coming years, with an estimated increase of USD 62.5 billion from 2025 to 2029. With a projected compound annual growth rate (CAGR) of 7.6%, this sector is becoming increasingly attractive to investors and consumers alike. The desire for convenient...

Continue Reading
Mag Mile Capital's $10.25 Million Equity Venture in Chicago

Updated Category News Views 261

Mag Mile Capital Secures Significant Equity for Urban Transformation Mag Mile Capital, Inc. (OTCQB: MMCP) has achieved a significant milestone by securing $10.25 million in joint venture equity aimed at an innovative office-to-multifamily conversion project in Chicago. This project, situated at 111 W. Illinois, aims to repurpose a prominent office space in the vibrant...

Continue Reading
Nourishing Dogs and Communities: The Launch of Purposeful Pup Treats

Updated Category News Views 243

Purposeful Pup Treats Unveils New Launch for Furry Friends Purposeful Pup Treats, a brand passionate about the welfare of pets, has proudly launched a new range of all-natural, single-ingredient dog snacks. These treats are created with high-quality European ingredients and designed not just for the health of dogs, but also to uplift and strengthen communities. Embracing...

Continue Reading
Collaboration of Linux Foundation and ATIS to Transform Telecom

Updated Category News Views 151

Strategic Partnership for Innovative Network Solutions The Linux Foundation and the Alliance for Telecommunications Industry Solutions (ATIS) have joined forces to create a transformative impact on next-generation network architectures. This collaboration paves the way for advancements in open source and open RAN technologies, which are becoming increasingly important in...

Continue Reading
Vallourec Expands Operations with Significant Contracts

Updated Category News Views 245

Vallourec's Strategic Contracts in Iraq Vallourec, a global leader in premium seamless tubular solutions, has recently cemented two significant contracts for the supply of Oil Country Tubular Goods (OCTG). These contracts, established with major players CNOOC and PetroChina, reflect Vallourec's strength and expertise in supporting drilling operations in challenging...

Continue Reading